Latest Research And Development News

Jindalee Lithium’s McDermitt Lithium Project has been designated a FAST-41 Transparency Project, enhancing federal permitting visibility and coordination to accelerate development in the US critical minerals sector.

Deep Yellow Ltd disclosed a quarterly cash flow report for Q1 2025, revealing a significant operating cash outflow but a robust cash reserve that supports an estimated 20 quarters of funding runway.

Nyrada Inc. posted a significant $2.46 million loss for H1 FY25, driven by increased R&D spend, while advancing its lead drug NYR-BI03 into first-in-human trials following regulatory approval.

Zelira Therapeutics has received a $1.15 million cash refund from the Australian Government’s R&D Tax Incentive Scheme, bolstering its working capital to advance clinical development and business operations.

Infomedia Ltd reported a solid half-year performance with a 2% revenue increase and a 63% surge in net profit, while announcing a strategic acquisition and a share buyback plan.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

Smart Parking Limited has reported a robust half-year performance with a 20% increase in revenue and a 70% rise in net profit, driven by international expansion and operational growth across multiple markets.

Audinate delivered 1H25 results above guidance despite a transitional year marked by inventory adjustments, with software revenue growth and strategic product launches setting the stage for a return to growth in FY26.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

Cochlear Limited posted a 6% increase in HY25 sales revenue driven by strong implant sales but anticipates FY25 profits at the lower end of guidance due to declining services revenue and rising cloud investments.

Cochlear Limited has reported a robust half-year performance with a 7% increase in underlying net profit and an 8% rise in interim dividends, driven by strong sales in cochlear and acoustic implants despite a decline in services revenue.